Visión generalGráficoPerfilEstadísticas claveBalance generalNoticiasTraderScreen

SPEXIS AG SF0,02/  CH0106213793  /

Lang & Schwarz
29/10/2024  7:43:01 Diferencia - Volumen Bid- Ask- Capitalización de mecado Dividendo A. P/E Ratio
0.010EUR - -
Volumen de negocios: -		 -Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 1.26 millonesEUR - -
GlobeNewswire 01/11/2023 Spexis Announces Changes to the Executive Committee
GlobeNewswire 06/10/2023 Spexis to host business update conference call on October 9, 2023
GlobeNewswire 29/09/2023 Spexis provides business update and announces financial results for the first half of 2023
GlobeNewswire 28/09/2023 Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
GlobeNewswire 15/08/2023 Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studie...
GlobeNewswire 28/06/2021 Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced ...
GlobeNewswire 08/06/2021 Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe ...
GlobeNewswire 01/06/2021 Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activi...
GlobeNewswire 18/05/2021 Polyphor to Present at the UBS Global Healthcare Virtual Conference
GlobeNewswire 05/03/2021 Polyphor Announces Financial Results for the Full-Year 2020
GlobeNewswire 26/02/2021 Polyphor to Present Full-Year 2020 Financial Results on March 5
GlobeNewswire 05/01/2021 Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Ann...
GlobeNewswire 22/12/2020 Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
GlobeNewswire 14/12/2020 Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to Continue Pha...
GlobeNewswire 11/12/2020 Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of ...
GlobeNewswire 24/11/2020 Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinica...
GlobeNewswire 29/10/2020 Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
GlobeNewswire 14/10/2020 Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic p...
GlobeNewswire 29/09/2020 Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receip...